THE WINNING CARE PROTOCOL

  • Description
  • Benefits
  • Indications
  • In Practice
  • Evidence

Discover the winning care protocol !

clean-start-description

Following the wound healing continuum, a chronic wound should be desloughed to promote granulation and close.

 

puce1 UrgoClean is the expert in desloughing. UrgoClean pad is made of hydro-desloughing fibres associated with TLC layer.

urgoclean-composition-2

It offers desloughing efficacy, resistance allowing one piece removal, atraumatic and pain-free removal. It is available in a wide range of dressings: UrgoClean pad and UrgoClean rope*. UrgoClean showed to deslough +50% vs hydrofibre in a Randomised Controlled Trial (1).

 

puce2 UrgoStart is a range of dressings with TLC-NOSF, a unique compound that has proven to accelerate healing in chronic wounds.  It provides healing efficacy, avoiding wounds becoming longstanding; improving patients’ quality of life and offering a cost-effective treatment. It is available in a wide range of dressings: UrgoStart, UrgoStart Contact and UrgoStart Border. UrgoStart was shown to accelerate wound healing x2 vs a neutral foam dressing in a double blind Randomised Controlled Trial.

 

urgostart-composition-3

Combining UrgoClean, to prepare the wound when the wound is sloughy, followed by UrgoStart to heal the wound, is the best way to heal.

* UrgoClean rope is not associated with a TLC layer to facilitate application in cavity wounds.
(1) Meaume S., Dissemond J, Addala A. et al. Evaluation of two fibrous wound dressings for the management of leg ulcers: Results of a European randomised controlled trial (EARTH RCT). Journal of Wound Care 2014; 23(3): 105 – 116. *Main criteria: relative reduction of wound surface area at W6 UrgoClean: 34.10% (n=80) vs Aquacel 34.40% (n=74) (NS)
 

Mode of action

 

 bm_urgoclean

In contact with exudate, the hydro-desloughing polyacrylate fibres of UrgoClean gel, swell and bind to the sloughy residue, absorbing and draining it to aid elimination (autolytic debridement). The creation of this gel maintains a moist environment, in contact with the wound, which promotes the healing of desloughed areas, trapping exudate and preventing their lateral diffusion.

In addition, thanks to the TLC, in the desloughed areas, fibroblast proliferation is promoted.

 

bm_urgostart

TLC (Technology Lipido-Colloid) combined with NOSF (Nano-Oligo Saccharide Factor) is a patented innovative technology which in contact with wound exudate forms a gel and creates a moist environment enabling the key cells involved in the repair process (fibroblasts, keratinocyrtes, macrophages) to exert their action.

TLC-NOSF interacts with the wound micro-environment of the wound by preventing the detrimental effect of Matrix Metallo Proteases (MMPs) which in excess in chronic wounds creates a continuous degradation of the extra-cellular matrix.

TLC-NOSF restores balance in the wound bed so granulation of chronic wounds can occur. UrgoStart thereby promotes faster wound healing.


This website is an international website. Some products or sizes can therefore be unavailable in some countries. For more information, please contact us.

BENEFITS FOR THE WOUND

  • Clean wound; a wound that is well-prepared (UrgoClean)
  • Neutralisation of excess proteases (UrgoStart)
  • Moist wound healing
  • No adherence to the wound: no damage to newly formed tissue

 

benefits-for-professionnalBENEFITS FOR HEALTH PROFESSIONALS

  • A simple and efficient protocol with associated benefits of desloughing and healing efficacy
  • Benefits clinically proven in Randomised Controlled Trials
  • All benefits of UrgoClean: safe desloughing, time saving treatment, exudate management, one piece removal, easy to apply and remove
  • All benefits of UrgoStart: faster healing avoiding wounds becoming longstanding with associated risks of complications and improving patients’ quality of life, cost-effective treatment, pain-free and atraumatic removal.

 

benefits-for-patientBENEFITS FOR PATIENTS

  • Clean wound (UrgoClean)
  • Faster recovery avoiding wounds becoming longstanding with associated risks of complications and improving patients’ quality of life (UrgoStart)
  • No adherence to the wound: pain-free dressing changes
  • Well-tolerated, very comfortable

The sequential treatment UrgoClean / UrgoStart is indicated for sloughy chronic wounds. UrgoClean is indicated at desloughing stage (yellow sloughy tissue > granulating tissue).

UrgoStart is indicated at granulation stage (granulation tissue > yellow sloughy tissue) and can be used until healing.

 

CONTRAINDICATIONS

UrgoClean

Organic mercury (Mercryl Lauryl, Dermachrome, Merfene) or hexamidine (Hexomedine) antiseptics and hydrogen peroxide (Oxygenated water)

For more information about contraindications for UrgoClean Rope and Pad, please refer to leaflet

* In the case of UrgoClean rope please refer to specific contraindications.

UrgoStart

In order not to delay any optimal treatment, UrgoStart/ UrgoStart Contact/UrgoStart Border are contraindicated in wounds such as cancerous wounds or fistula wounds which may reveal a deep abcess.

Do not use if there is a known sensitivity to UrgoStart/ Urgostart Contact /UrgoStart Border

Instructions for use

UrgoClean

  • Clean the wound as per local protocol and rinse with normal saline.
  • The use of UrgoClean pad does not dispense with the need for associated mechanical debridement when required.
  • UrgoClean pad can be cut using sterile scissors to fit the dressing size to the wound if necessary.
  • Using the tabs, remove the protective film.
  • Apply the soft-adherent side of UrgoClean pad to the wound.
  • If required, cover UrgoClean pad with a secondary dressing suitable for the location and level of wound exudate.
  • Secure the dressing in place with a suitable bandage, adhesive tape. Apply a compression bandage when prescribed.
  • UrgoClean pad should be changed every 1 to 2 days during the wound desloughing phase, then as often as required (up to 7 days) depending on the level of exudate and the clinical condition of the wound.
* In the case of UrgoClean Rope, please refer to specific application method.

 

UrgoStart

When the wound is desloughed (granulation tissue > yellow sloughy tissue) and prepared to heal, UrgoStart can be initiated.

  • Clean the wound as per local protocol and rinse with normal saline.
  • If an antiseptic is first used, rinse the wound thoroughly with saline solution before applying UrgoStart.
  • UrgoStart can be cut using sterile scissors to fit the dressing size to the wound if necessary.
  • Using the tabs, remove the protective film.
  • Apply the soft-adherent side of UrgoStart to the wound.
  • If required, cover UrgoStart with a secondary dressing suitable for the location and level of wound exudate.
  • Secure the dressing in place with a suitable bandage, adhesive tape. Apply a compression bandage when prescribed.
  • UrgoStart should be changed every 2 to 4 days, and left in place for up to 7 days depending on the level of exudate and the clinical condition of the wound.
  • The recommended duration of treatment is a minimum of 8 weeks until wound healing
* In the case of UrgoStart Heel, UrgoStart Border or UrgoStart Contact please refer to specific application method.

 

PRECAUTIONS FOR USE

UrgoClean

  • As the soft-adherent layer of UrgoClean pad adheres to surgical gloves (latex), it is recommended to use the protective wings to aid application.
  • Due to the non-occlusive nature of this dressing, UrgoClean Pad can be used on colonised wounds under close medical supervision.
  • During the desloughing process, the wound may appear to increase in size due to the gradual elimination of sloughy tissue.
  • Do not combine UrgoClean Pad or Rope with hydrogen peroxide, organic mercury or hexamidine antiseptics.
  • Discard any unused parts of the dressing.
  • Check that the sterility protector is intact before use.
  • Single-use, individual and sterile dressing: re-using a single-use product may lead to risks of infection.
  • Do not re-sterilise the dressing.
* In the case of UrgoClean rope please refer to specific precautions.

 

UrgoStart

  • As the soft-adherent layer of UrgoStart adheres to surgical gloves (latex), it is recommended to use the protective wings to aid application.
  • If signs of critical colonisation are present, suitable treatment is recommended before using UrgoStart.
  • In case of an atypical ulcer presenting induration or overgranulation, UrgoStart should only be used after checking the absence of wound-related malignancy in order not to delay the diagnosis.
  • The action of the product on the healing process may possibly cause stinging or painful sensations at the start of treatment with UrgoStart. This rarely warrants suspension of treatment.
  • In the absence of clinical data as a first line treatment in acute wounds, and in the treatment of Epidermolysis bullosa (even for longstanding lesions), it is not recommended to use UrgoStart.
  • Discard any unused parts of the dressing.
  • Check that the sterility protector is intact before use.
  • Single-use, individual and sterile dressing: re-using a single-use product may lead to risks of infection.
  • Do not re-sterilise the dressing.
* In the case of UrgoStart Border or UrgoStart Contact please refer to specific precautions.

 

SIZES AVAILABLE

UrgoClean pad

UrgoStart

  • 6×6 cm
  • 10×10 cm; 10×12 cm
  • 15×15 cm
  • 15×20 cm
  • Rope 2.5×40 cm; 5×40 cm
  • 6×6 cm
  • 10×10 cm; 10×12 cm; 13×12 cm
  • 15×15 cm; 15×20 cm
  • Heel 12×19 cm

urgoclean

urgostart_microadherent_13x12_2013

 
* In the case of UrgoStart Border or UrgoStart Contact please refer to page.

This website is an international website. Some products or sizes can therefore be unavailable in some countries. For more information, please contact us.
earth-study-march-2014 urgo-meeting-report-8sw-Fri  
Evaluation of two fibrous wound dressings for the management of leg ulcers: Results of a European randomised controlled trial (EARTH RCT) Stepping up to customised
wound care
 
Download Download  

 

A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-OligoSaccharide Factor wound dressing in the local management of venous leg ulcers

Meaume S. et al, Wound Rep Reg (2012) 20 500–511 © 2012 by the Wound Healing Society

Venous leg ulcers (VLUs) are the most prevalent chronic wounds in western countries with a heavy socioeconomic impact. Compression therapy is the etiologic treatment of VLU but until now no wound dressing has been shown to be more effective than another. The aim of this study was to assess the efficacy of a new dressing in the management of VLU. Adult patients presenting a noninfected VLU and receiving effective compression therapy were enrolled in this randomized, controlled, double-blind trial. The VLUs were assessed every 2 weeks for 8 weeks. The primary study outcome was the relative Wound Area Reduction (WAR, in %), and the secondary objectives were absolute WAR, healing rate, and percentage of wounds with > 40% surface area reduction. One hundred eighty-seven patients were randomly allocated to treatment groups. Median WAR was 58.3% in the Lipido-Colloid Technology-Nano-OligoSaccharide Factor (TLC-NOSF) dressing group (test group) and 31.6% in the TLC dressing group (control group) (difference: – 26.7%; 95% confidence interval: – 38.3 to – 15.1%; p = 0.002). All other efficacy outcomes were also significant in favor of the TLC-NOSF dressing group. Clinical outcomes for patients treated with the new dressing are superior to those patients treated with the TLC dressing (without NOSF compound), suggesting a strong promotion of the VLU healing process.

Last update : November 23, 2017